Back to Dashboard
40

AZTA

🏥 Healthcare

Azenta, Inc.

Conservative #847Aggressive #774Moderate RiskHigh 100
$27.71-0.61%
Day High$28.13
Day Low$27.45
Volume0.0M
Mkt Cap$1.3B
52W Low $2452W High $48
Market Cap
$1.3B
P/E Ratio
N/A
Rev Growth
3.6%
Sector avg: 161.5%
Earnings Growth
66.2%
Profit Margin
-9.7%
Sector avg: -3292.7%
Debt/Equity
0.06

Why This Score

AZTA scores 40.3 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.

Strengths
  • Minimal leverage (D/E 0.06) provides financial flexibility and downside protection.
  • High conviction (100/100) — fundamental and ML signals agree on this stock.
Risk Factors
  • Liquidity concern: Limited trading volume or float results in a 2-point penalty for execution risk.
  • Above-average volatility (14.9%) may not suit conservative risk tolerance.

Minor adjustments (-2.0 points) applied. AZTA's rank of #847 primarily reflects its factor profile relative to the conservative weight vector.

Score Breakdown

Overall Score40.3
Fundamental Score39.3
ML Score34.0

Score by Horizon

3 Month
64.9
6 Month
72.6
Primary
1 Year
76.4

Quality Assessment

B
Earnings Grade
Solid fundamentals with minor quality concerns
Quality Flags
High accrual ratio (205.0%) — earnings quality concern

Position Sizing

Suggested Allocation
5%
Confidence
medium

Score Composition Waterfall

How each component affects the final score
Backtested Scoring Levers (IC-calibrated from 30y ElasticNet)
Weinstein (12.1%)
50
Basing
Sentiment (2.5%)
52
Neutral
Analyst (6.4%)
65
Favorable
Tradability (post-hoc)
79
Grade B
Base
36.3
SHAP
+1.1
Factors
+0.6
Conviction
+2.3
Final
40.3
Positive adjustment
Negative adjustment
Base blend
Final score

Signal SegmentsComputed from ML features

Fundamental (Valuation, Quality, Growth)59.0
Technical (Momentum, Weinstein, Volatility)45.0
External (Sentiment, Analyst, Macro)79.0
Scores below 50 indicate weakness in that segment relative to the universe.

Data Quality

Score
Features
Confidence
Feature Coverage89%

Growth Estimates

Short-term
-0.4% to +3.9%
Medium-term
+0.0% to +6.6%
Long-term
+0.5% to +9.4%

ML Model Core Features100 trained inputs → ML Score: 34

These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.

Analyst Intelligence
Consensus Score64.6/100
Target Upside+50.7%
Coverage12 analysts
Market Sentiment
Sentiment Score52.3/100
News Volume1 articles
Technical Stage
Weinstein Stage1 — Basing
12M Momentum-0.3%
6M Momentum-0.1%
Volatility+0.1%
Momentum & Technical
Momentum Acceleration-28.1%
Momentum ConsistencyWeak (0.18)
Relative Strength vs Sector-58.8%
Trend Strength (ADX Proxy)Moderate (2.3)
Momentum Quality-0.253
Momentum BreadthNarrow
Macro Regime
Bull RegimeYes
High Vol RegimeNo
S&P 500 Return+25.0%
Yield Curve-0.1bp

Sector-Relative AnalysisIn-model features

Value Trap Signal
15%
Low risk
Sector RevGr Rank
P46
Revenue growth vs Healthcare peers
Sector PE Rank
P40
Valuation vs Healthcare peers
Sector FCF Rank
P69
Free cash flow vs Healthcare peers
Growth Deviation
-0.0σ
Z-score vs sector median
Stagnation Flag
NO
Not flagged

Analysis Signals

Scoring Factors
Fundamental score of 74 relative to sector peers74/100
Machine learning model ranks this stock at the 76th percentileP76
ML model weight reduced to 9% due to macro conditions: market in extended rally phase; yield curve inverted (recession indicator); late-cycle economic indicators detected9% ML weight
SHAP feature alignment: +1.8pt (features align with model priorities)
Blend: 91% fund (74.0) + 9% ML (73.6) + SHAP(+1.8) = 75.8
Factor quality: +1.0pt (multi-factor composite)
Risk assessment: moderate. Annualized volatility 14.9%. Max drawdown 26% (-7.4 pts). Price momentum -34% (-5.9 pts)Moderate
Market cap adjustment: -8.0 points ($1.3B market cap)-8.0 pts
Conviction bonus: +3.6pt (conviction=100)
Risk Factors
Earnings quality grade B: adequate earnings quality with minor concerns. Score adjusted by -5 pointsGrade B
Quality concern: High accrual ratio (205.0%) — earnings quality concernFlag

Sector Peer Comparison(Healthcare — Rank #132 of 344 stocks)

StockScoreP/ERev GrowthMarginMkt Cap
AZTA40.3N/A3.6%-9.7%$1.3B
INCY89.615.821.2%25.0%$20.1B
GMAB85.513.122.8%36.4%$18.5B
CPRX82.213.723.5%37.6%$3.0B
VRTX78.032.18.9%32.9%$126.0B
ASND75.716.698.0%-31.7%$13.3B
NBIX74.726.521.4%16.7%$12.5B
ALKS74.616.5-6.4%23.9%$5.5B
AMGN73.826.010.0%21.0%$199.0B
ARGX73.635.178.6%38.0%$50.9B
HOLX73.331.11.7%13.8%$16.8B
REGN72.719.41.0%31.4%$84.9B
ISRG72.361.720.5%28.4%$172.5B
EXEL71.915.17.0%33.7%$11.7B
KRYS71.041.4473.0%30.7%$8.0B
HALO70.216.822.4%43.7%$9.3B
Sector Average37.1252.3161.5%-3292.7%

Market Sentimentvia FMP

Analyst Consensus
Buy12 analysts
Buy: 7Hold: 5
Price Target
$43consensus
Low $38Median $45High $45
+55.2% to consensus target

Company Overviewvia FMP

Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.

CEO
John Marotta
Employees
3,000
Beta
1.34
Industry
Medical - Instruments & Supplies
FMP-Identified Peers

Technical Picturecomputed from daily prices

RSI (14)
50.7
Neutral
Trend
Bearish
10-day vs 50-day MA
From 52W High
-41.2%
High: $47.55
From 52W Low
+17%
Low: $23.91
Moving Averages
10-Day
$28.60
Below
20-Day
$30.70
Below
50-Day
$34.40
Below
200-Day
$31.80
Below
60-Day Support
$27
60-Day Resistance
$41.73
Weinstein Stage Analysisbased on 200-day SMA framework
Stage 1 — BasingScore: 34/100

Stock is building a base after a decline. The 200-day moving average is flattening. Watch for a breakout above the 200-day SMA on increased volume.

Monitor for breakout above 200-day SMA on volume
Transition signal: 1→2
Price vs 200 SMA
-12%
200 SMA Slope (60d)
+0.13%
Flattening
Volume Ratio
0.81x
10d avg vs 50d avg
Days in Stage
16
Confidence: 80%

Financial Statementslast 4 quarters via FMP

MetricQ1 2025Q4 2025Q3 2025Q2 2025
Revenue$149M$159M$144M$143M
Gross Profit$64M$72M$68M$66M
Operating Income$-5M$3M$2M$-7M
Net Income$-15M$51M$-53M$-40M
EPS (Diluted)$-0.34$1.02$-1.15$-0.88
Gross Margin42.9%45.4%47.1%45.9%
Operating Margin-3.3%1.8%1.1%-5.2%
Net Margin-10.4%32.0%-36.7%-28.2%

Why This Stock

Healthcare

Tradability FilterGrade B — 79/100Score impact: -11.7pt

Volume
91
781K avg/day
Dollar Vol
81
$22M/day
Float
71
41M shares
Mkt Cap
46
$1.3B
Range
100
99% spread
Composite Liquidity Score79/100
FDCBA

Growth Projection Adjustment

0.7x dampening
weinstein basing

Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.

Free Float
88.3%
Outstanding Shares
46M
Bid-Ask Spread
99.0%
Institutional Tradable
Yes

Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.